Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01888315 |
Recruitment Status
:
Recruiting
First Posted
: June 27, 2013
Last Update Posted
: June 27, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Heart Failure Chronic Kidney Disease Diabetes Heart Rhythm Disorders | Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix | Phase 1 Phase 2 |
Inclusion Criteria
- Individual is 18 years of age.
- Individual agrees to have all procedures performed, and is competent and willing to provide written, informed consent to participate in the registry.
- Patient scheduled for renal sympathetic denervation using market-released device.
Exclusion Criteria
- In the eyes of the treating physician, the renal artery anatomy would interfere with safe cannulation of the renal artery or meets local standards for surgical repair.
- Individual has any serious medical condition, which in the opinion of the treating physician may adversely affect the safety and/or effectiveness of the participant (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, significant anemia, etc.).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1000 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation on Different Organ Systems in Patients With Increased Sympathetic Activity |
Study Start Date : | January 2011 |
Estimated Primary Completion Date : | January 2021 |
Estimated Study Completion Date : | January 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Catheter-based renal denervation
One procedure will be performed using one of the CE-marked devices for renal denervation: Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix |
Device: Renal denervation with Symplicity Flex Medtronic/Ardian
Renal denervation using CE-marked devices will be performed according to best medical practice.
Device: Renal denervation with EnligHTN St. Jude Medical
Renal denervation using CE-marked devices will be performed according to best medical practice.
Device: Renal denervation with Paradise Recor
Renal denervation using CE-marked devices will be performed according to best medical practice.
Device: Renal denervation with V2 Vessix
Renal denervation using CE-marked devices will be performed according to best medical practice.
|
No Intervention: Medical therapy
Best medical therapy using guideline recommended drugs in each disease state.
|
- Safety and efficacy of renal denervation [ Time Frame: Baseline to 6 months ]
Effect on blood pressure including office, ABPM, and home-based measurements.
Number of adverse events (death, stroke, myocardial infarction, new dialysis, and congestive heart failure).
Changes of antihypertensive medications.
Effects on renal function assessed with glomerular filtration rate.
Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.
- Effect of renal denervation on different organ systems. [ Time Frame: Baseline, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months ]
Myocardial function and geometry using echo and MRI.
Heart rate changes and arrhythmias.
Glucose metabolism and insulin resistance (fasting and during oGTT).
Hospitalization rates (eg. hypertensive emergencies, heart failure, etc).
- Safety and efficacy of renal denervation [ Time Frame: Baseline, 3, 12, 18, 24, 30, 36, 42, 48, 54, 60 months ]
Effect on blood pressure including office, ABPM, and home-based measurements.
Number of adverse events (death, stroke, myocardial infarction, new dialysis, and congestive heart failure).
Changes of antihypertensive medications.
Effects on renal function assessed with glomerular filtration rate.
Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Individual is 18 years of age.
- Individual agrees to have all procedures performed, and is competent and willing to provide written, informed consent to participate in the registry.
- Patient scheduled for renal sympathetic denervation using market-released device.
Exclusion Criteria
- In the eyes of the treating physician, the renal artery anatomy would interfere with safe cannulation of the renal artery or meets local standards for surgical repair.
- Individual has any serious medical condition, which in the opinion of the treating physician may adversely affect the safety and/or effectiveness of the participant (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, significant anemia, etc.).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01888315
Contact: Felix Mahfoud, MD | +4968411621346 | felix.mahfoud@uks.eu | |
Contact: Michael Böhm, MD | +4968411623372 | michael.boehm@uks.eu |
Germany | |
University Hospital Saarland | Recruiting |
Homburg/Saar, Germany, 66421 | |
Contact: Michael Böhm, MD | |
Contact: Felix Mahfoud, MD |
Study Director: | Felix Mahfoud, MD | University Hospital, Saarland | |
Principal Investigator: | Michael Böhm, MD | University Hospital, Saarland |
Responsible Party: | University Hospital, Saarland |
ClinicalTrials.gov Identifier: | NCT01888315 History of Changes |
Other Study ID Numbers: |
Symplicity Extension |
First Posted: | June 27, 2013 Key Record Dates |
Last Update Posted: | June 27, 2013 |
Last Verified: | June 2013 |
Keywords provided by University Hospital, Saarland:
Hypertension Heart Failure Sympathetic activity |
Additional relevant MeSH terms:
Hypertension Heart Failure Kidney Diseases Renal Insufficiency, Chronic Arrhythmias, Cardiac Vascular Diseases |
Cardiovascular Diseases Heart Diseases Urologic Diseases Renal Insufficiency Pathologic Processes |